25 February 2026
Novo Nordisk and Vivtex Collaborate on Oral Medicines for Obesity and Diabetes
The partnership aims to develop oral biologics for obesity and diabetes, leveraging Vivtex's technology for better bioavailability and Novo Nordisk's expertise in global development and commercialization.